Barclays reaffirmed its ‘Overweight’ rating on the LLY stock and its $1,350 price target on Tuesday, according to a TipRanks ...

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Investomine’s Substack. In this ...

Eli Lilly (LLY) stock is lower today, after HSBC downgraded it to "reduce" from "hold," citing an inflated obesity drug market ...

Eli Lilly (LLY) stock declined after HSBC downgrade to Reduce with $850 price target, citing obesity drug market risks and ...

Eli Lilly (NYSE:LLY) shares have pulled back sharply, falling  9% over the past month, and 13% year-to-date. Most Wall Street ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% ...

Biggest stock gainers. Lemonade +15% - Shares gained after Morgan Stanley upgraded the stock to Overweight from Equal-Weight, ...

The way that people discuss LLY these days is virtually unique. Quieter tones—almost like a mutual understanding among ...

LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.

HSBC downgraded this dividend-paying health care giant. Here's what investors should know before the obesity drug race heats ...

Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term stocks to invest in according to billionaires. Eli Lilly and ...